Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Kumamoto, A. Harumatsu, K. Sakaue, T. Hamada, M. Yamamoto, T. Hamasaki, K. Mizuno, I. Higashimoto, T. Samukawa, H. Inoue (Kagoshima City, Japan). Elevation of serum napsin A levels in patients with hypersensitive pneumonia. Eur Respir J 2013; 42: Suppl. 57, 2355

Member's Comments

No comment yet.

Related content which might interest you: Seasonal variation of serum KL-6 levels in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 1 Year: 2014 Serum heat shock protein 47 levels in patients with drug induced lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Elevation of serum napsin A in interstitial lung diseases in comparison with KL-6 and surfactant protein-D Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Usefulness of serum bird specific antibody levels in patients with interstitial pneumonia Source: International Congress 2016 – Orphan diseases II Year: 2016 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Comparative role of serum cathepsin S concentrations for differential diagnosis of sarcoidosis from other lung diseases Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Serum procalcitonin is useful in differentiating between drug-induced pneumonitis and bacterial pneumonia Source: International Congress 2014 – ILDs 5 Year: 2014 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Elevated neutrophil lymphocyte ratio and T4 levels can be predisposing factors for silicosis Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods Year: 2016 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016 Conduct of a biomarker study in bronchiectasis patients: Correlation of neutrophil elastase activity and inflammatory load in induced sputum Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 The clinical features of 13 patients with interstitial pneumonia with positive anti-glycyl-tRNA synthetase autoantibodies Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Source: International Congress 2014 – IPF and surroundings Year: 2014 Relation of plasma osteopontin levels with the clinical course in patients with COPD Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016